2019 WCLC新辅助免疫治疗新进展
——蔡修宇（中山大学附属肿瘤医院）
内容概要：
一、OA13.07- Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
二、OA13.06- Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer-NEOSTRA Study
三、OA13.05-NADIM Study: Updated Clinical Research and Outcomes (Nivolumab+Chemo)
三、JCSE01.10-Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Non-Small Cell Lung Cancer
四、P2.04-89-Neoadjuvant Pembrolizumab in Early Stage Non-Small Cell Lung Cancer (NSCLCL): Toxicity, Efficacy, and Surgical Outcomes
五、P2.04-28-NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Eearly-Stage(I-IIIA) Non-Small Cell Lung Cancer
六、P1.18-02 The AEGEAN phase 3 trial of neoadjuvant/adjuvant durvalumabin patients with resectable Stage II/III NSCLC
新辅助免疫治疗的重要研究小结：
1、CM159：NIVO单药MPR 率达45%,RECIST ORR 9%.
2、LCMC3：Atezo单药MPR 率达18%,RECIST ORR 7%.
3、Sintilimab：Sinti单药MPR率达45.5%，RECIST ORR 13.6%.
4、NEOSTAR：NIVO单药MPR率达17%，RECIST ORR 22%.
5、NEOSTAR：NIVO+IPI的MPR率达33%,RECIST ORR 19%.
6、NADIM：NIVO+PC联合MPR率达85.36%，RECIST ORR 78.5%.
详细内容：
错过的会议或内容也许可以在这里补，欢迎扫码关注IO学社！
IO相关热文：
NEOSTAR：纳武利尤单抗和纳武利尤单抗联合伊匹单抗用于早期 NSCLC 新辅助治疗的研究结果
一项评估纳武利尤单抗、纳武利尤单抗+贝伐珠单抗或纳武利尤单抗联合伊匹木单抗在转移性肾细胞癌患者的应用
【ASCO】中国医学科学院肿瘤医院院长赫捷教授牵头的信迪利单抗用于可切除非小细胞肺癌新辅助治疗的临床研究数据公布
声明：
